Prediction of Coronary Artery Disease Severity by Epicardial Adipose Tissue Thickness

October 11, 2017 updated by: Osama Fekry

Predictive Value of Epicardial Fat Thickness for Disease Severity in Coronary Artery Disease Patients

is to test the hypotheses that epicardial adipose tissue can be a marker of severity of coronary artery disease in myocardial infarction patients

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

epicardial adipose tissue is defined as the adipose tissue between the visceral pericardium and the outer margin of the myocardium which can be considered an endocrine organ that secretes pro-inflammatory and anti-inflammatory cytokines and chemokines including adiponectin.as investigators know, inflammatory response is an important factor in the coronary atherogenesis. Therefore,epicardial adipose tissue is likely to be connected with the severity of coronary artery disease.Recent studies showed that the thickness of the epicardial adipose tissue in patients with coronary artery disease was greater than that with normal coronary arteries.

epicardial adipose tissue will be assessed using transthoracic echocardiography and cardiac magnetic resonance which allows for an accurate volumetric quantification of epicardial fat.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 90 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

acute myocardial infarction patiens not previously underwent percutaneous coronary angiography or coronary artery bypass grafting

Description

Inclusion Criteria

  1. Normal thoracic shape
  2. Sinus rhythm
  3. without severe respiratory diseases

Exclusion Criteria:

  1. contraindication for cardiac magnetic resonance.
  2. Patients who previously underwent coronary artery bypass grafting or percutaneous coronary angiography prior to admission
  3. history of chronic kidney disease with glomerular filtration rate <30 mL/min
  4. pericardial and/or pleural effusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
myocardial infarction patients
transthoracic echocardiography and cardiac magnetic resonance
Radiation: echocardiography and cardiac magnetic resonance
transthoracic echocardiography and magnetic resonance imaging of the heart

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measurement of epicardial adipose tissue as marker of severity of coronary artery disease in myocardial infarction patients.
Time Frame: one year
epicardial adipose tissue measurement using transthoracic echocardiography and cardiac magnetic resonance
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Osama Fekry

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

November 1, 2017

Primary Completion (Anticipated)

December 1, 2017

Study Completion (Anticipated)

September 1, 2018

Study Registration Dates

First Submitted

October 6, 2017

First Submitted That Met QC Criteria

October 11, 2017

First Posted (Actual)

October 12, 2017

Study Record Updates

Last Update Posted (Actual)

October 12, 2017

Last Update Submitted That Met QC Criteria

October 11, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • epicardial adipose tissue (Other Identifier: Gulhane SM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe